Astria Therapeutics Inc [ATXS] stock prices are up 6.85% to $4.37 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ATXS shares have gain 1.86% over the last week, with a monthly amount drifted -11.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Astria Therapeutics Inc [NASDAQ: ATXS] stock has seen the most recent analyst activity on April 29, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $47. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on January 31, 2025, and set its price target to $26. On July 29, 2024, TD Cowen initiated with a Buy rating and assigned a price target of $35 on the stock. Evercore ISI started tracking the stock assigning a Outperform rating and suggested a price target of $18 on March 28, 2023.
The stock price of Astria Therapeutics Inc [ATXS] has been fluctuating between $3.56 and $12.92 over the past year. Currently, Wall Street analysts expect the stock to reach $22.5 within the next 12 months. Astria Therapeutics Inc [NASDAQ: ATXS] shares were valued at $4.37 at the most recent close of the market. An investor can expect a potential return of 414.87% based on the average ATXS price forecast.
Analyzing the ATXS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.33 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.11 points at the first support level, and at 3.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.54, and for the 2nd resistance point, it is at 4.71.
Ratios To Look Out For
It’s worth pointing out that Astria Therapeutics Inc [NASDAQ:ATXS]’s Current Ratio is 17.39. Further, the Quick Ratio stands at 17.39, while the Cash Ratio is 3.12.
